CAR T-cell therapy after first treatment for high-risk lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a type of immunotherapy called axicabtagene ciloleucel (a CAR T-cell therapy) can improve outcomes when given right after initial treatment for high-risk large B-cell lymphoma. It is for people who have not yet started treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old
- You must have a type of lymphoma called large B-cell lymphoma that has not been treated before and tests positive for CD19
- You must be generally healthy enough to undergo the procedure (good organ function, no active infections)
- You must not have lymphoma that has spread to your brain or spinal cord
- You must not have had a stem cell or organ transplant before
- You must not have received certain other treatments like other CAR T-cell therapies or immune checkpoint therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the CAR-T cell therapy axicabtagene ciloleucel (a type of immunotherapy made from your own immune cells) can be effective as a first treatment for people with aggressive large B-cell lymphoma that hasn't responded well after two rounds of chemoimmunotherapy. It's designed for patients with high-risk features who might need a stronger approach early on.
This trial tests a special immune cell therapy (CAR-T cells) for people with a type of aggressive lymphoma that returned more than a year after first treatment. It aims to see if this therapy can help control the cancer again.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
This trial tests whether a second infusion of a CAR-T cell therapy called Axi-cel, given early based on a blood test (ctDNA), can help people with relapsed or hard-to-treat large B-cell lymphoma. If you had a partial response or your ctDNA stayed positive after the first dose, you may be eligible.
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
This early-stage trial tests an automated version of axicabtagene ciloleucel (a CAR-T cell therapy) for large B-cell lymphoma that has come back or stopped responding to initial chemotherapy. CAR-T therapy uses your own immune cells, modified in a lab to fight cancer cells.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.